AZD4041 + Placebo
Phase 1Completed 0 views this week 0 watching💤 Quiet
Interest: 29/100
29
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Smoking Cessation
Conditions
Smoking Cessation
Trial Timeline
Oct 3, 2019 → Jan 2, 2022
NCT ID
NCT04076540About AZD4041 + Placebo
AZD4041 + Placebo is a phase 1 stage product being developed by AstraZeneca for Smoking Cessation. The current trial status is completed. This product is registered under clinical trial identifier NCT04076540. Target conditions include Smoking Cessation.
What happened to similar drugs?
17 of 20 similar drugs in Smoking Cessation were approved
Approved (17) Terminated (0) Active (3)
Hype Score Breakdown
Clinical
6
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04076540 | Phase 1 | Completed |
Competing Products
20 competing products in Smoking Cessation